Free Trial

Atara Biotherapeutics (ATRA) Earnings Date, Estimates & Call Transcripts

Atara Biotherapeutics logo
$5.15 +0.39 (+8.19%)
As of 04:00 PM Eastern

Atara Biotherapeutics Earnings Summary

Atara Biotherapeutics released Q4 2025 earnings on March 16, 2026, reporting an EPS of -$0.25, which beat the consensus estimate of -$0.68 by $0.43. Quarterly revenue was reported to be $1.60 million, above analyst estimates of $0.70 million. With a trailing EPS of $3.12 and a P/E Ratio of 1.65, Atara Biotherapeutics' earnings are expected to remain at $0.20 per share in the coming year.

Upcoming
Earnings Date
May. 6Estimated
Consensus EPS
(Mar. 16)
-$0.68
Actual EPS
(Mar. 16)
-$0.25 Beat By $0.43
Actual Revenue
(Mar. 16)
$1.60M

Q4 2025 Earnings Resources

ATRA Upcoming Earnings

Atara Biotherapeutics' Q1 2026 earnings is estimated for Wednesday, May 6, 2026, based on past reporting schedules

Get Atara Biotherapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

ATRA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ATRA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Atara Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261$2.46$2.46$2.46
Q2 20261-$0.57-$0.57-$0.57
Q3 20261-$0.52-$0.52-$0.52
Q4 20261-$0.49-$0.49-$0.49

Atara Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2026
(Estimated)
--------
3/16/2026Q4 2025-$0.68-$0.25+$0.43-$0.36$0.70M$1.60M
11/12/2025Q3 2025-$0.83-$0.32+$0.51-$0.32$2.74M$3.45M
8/11/2025Q2 2025-$0.32$0.19+$0.51$0.19$4.23M$17.58M
5/15/2025Q1 2025-$3.07$3.50+$6.57$3.50$4.30M$98.10M
3/7/2025Q4 2024-$3.82-$1.19+$2.63-$1.19$20.58M$32.75M
11/12/2024Q3 2024-$3.77-$2.93+$0.84-$2.93$23.00M$40.19M
8/12/2024Q2 2024-$1.56-$3.10 -$1.54-$3.10$48.30M$28.64M
5/9/2024Q1 2024-$9.25-$5.75+$3.50-$0.23$27.00M$27.36M

Data powered by Fiscal.ai.

Atara Biotherapeutics Earnings - Frequently Asked Questions

Atara Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 6th, 2026 based off last year's report dates. Learn more on ATRA's earnings history.

In the previous quarter, Atara Biotherapeutics (NASDAQ:ATRA) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.68) by $0.43. Learn more on analysts' earnings estimate vs. ATRA's actual earnings.

Atara Biotherapeutics (NASDAQ:ATRA) has a recorded annual revenue of $120.77 million.

Atara Biotherapeutics (NASDAQ:ATRA) has a recorded net income of $32.69 million. ATRA has generated $3.12 earnings per share over the last four quarters.

Atara Biotherapeutics (NASDAQ:ATRA) has a trailing price-to-earnings ratio of 1.65 and a forward price-to-earnings ratio of 25.75.

Atara Biotherapeutics' earnings are expected to stay at $0.20 per share in the next year.


This page (NASDAQ:ATRA) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners